Monday, October 3, 2022


Biotechnology News Magazine

BIO-CAT Microbials Publishes Safety Manuscript on Proprietary New Bacillus Strain

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

BIO-CAT Microbials continues to scale up their probiotic pipeline with their latest microbial strain, Bacillus subtilis BS50. This strain was identified as the top contender after undergoing a rigorous and competitive screening against several thousand strains held within BIO-CAT’s propriety library.

BIO-CAT Microbials utilizes in-house nanopore sequencing technology to sequence the complete genome of each strain. Each strain is screened for key safety parameters and beneficial properties such as the ability to make relevant bioactive compounds. Genome predicted bioactivities are then confirmed by laboratory testing followed by clinical trial.

The safety of BS50 is the focus of BIO-CAT Microbials’ latest peer reviewed publication. Published in Microorganisms on May 17th, 2022, this manuscript lays the foundation of safety as BIO-CAT Microbials seeks GRAS status for the new Bacillus strain. The efficacy of BS50 as a human probiotic will be explored at the upcoming Probiota Americas, June 1-3 2022, in Washington D.C.

“We are proud to announce the safety and efficacy of our newest strain. This is the culmination of many months of screening and development, and represents yet another example of BCM’s continued strain development.” said Dr. Jessica Spears, PhD, Director of R&D at BIO-CAT Microbials.

BIO-CAT Microbials continues to be an industry leader in microbial solutions. The company recently announced a new capital expansion in Troy, Virginia, adding redundancy and significantly expanding capacity, which is currently underway with an anticipated completion date in 2023.

BIO-CAT Microbials, LLC was founded in 2004 by BIO-CAT Inc., an enzyme industry leader located in Troy, Virginia. For 17 years, BIO-CAT Microbials, LLC has focused on three core life science verticals: human, animal, and crop nutrition. BIO-CAT Microbials, LLC continues to be an innovative global biotech leader that supports customers with advanced microbial solutions. As industry experts, their science-led team specializes in strain development, fermentation, and product development.

Other clinical trial news can be found here.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine